IRAK1: Oncotarget in MDS and AML

Oncotarget

Volumn 5, Issue 7, 2014, Pages 1699-1700

  Beverly, Levi J ^a   Starczynowski, Daniel T ^b,c  

^a University of Louisville School of Medicine   (United States)

^b UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^c CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 1 RECEPTOR; INTERLEUKIN 1 RECEPTOR ASSOCIATED KINASE 1; INTERLEUKIN 1 RECEPTOR ASSOCIATED KINASE INHIBITOR; MESSENGER RNA; NAVITOCLAX; PHOSPHOTRANSFERASE INHIBITOR; TOLL LIKE RECEPTOR; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED FACTOR 6; UNCLASSIFIED DRUG; VENETOCLAX; ANILINE DERIVATIVE; ANTINEOPLASTIC AGENT; INTERLEUKIN 1 RECEPTOR ASSOCIATED KINASE; IRAK1 PROTEIN, HUMAN; PROTEIN KINASE INHIBITOR; SULFONAMIDE;

ACUTE GRANULOCYTIC LEUKEMIA; BCL2 GENE; CELL SURVIVAL; DRUG POTENTIATION; EDITORIAL; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENE OVEREXPRESSION; GENE TARGETING; HUMAN; IRAK1 GENE; MULTIGENE FAMILY; MYELODYSPLASTIC SYNDROME; ONCOGENE; PROTEIN FUNCTION; ANTAGONISTS AND INHIBITORS; CELL PROLIFERATION; DRUG EFFECTS; LEUKEMIA, MYELOID, ACUTE; METABOLISM; MOLECULARLY TARGETED THERAPY; MYELODYSPLASTIC SYNDROMES; SIGNAL TRANSDUCTION; TRANSFORMED CELL LINE;

ANILINE COMPOUNDS; ANTINEOPLASTIC AGENTS; CELL LINE, TRANSFORMED; CELL PROLIFERATION; CELL SURVIVAL; HUMANS; INTERLEUKIN-1 RECEPTOR-ASSOCIATED KINASES; LEUKEMIA, MYELOID, ACUTE; MOLECULAR TARGETED THERAPY; MYELODYSPLASTIC SYNDROMES; PROTEIN KINASE INHIBITORS; SIGNAL TRANSDUCTION; SULFONAMIDES;

EID: 84899001236     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.1880     Document Type: Editorial

References (6)

1. Rhyasen GW et al. Cancer Cell. 2013; 24: 90-104.
2. Rhyasen GW et al. Exp Hematol. 2013; 41: 1005-7.
3. Barreyro L et al. Blood, 2012.
4. Wei Y et al. Leukemia. 2013; 27: 1832-40.
5. Parker, J.E., et al. Blood, 2000; 96: 3932-8.
6. Casson L et al. PLoS One. 2013; 8: e54525.